ValiMed Pay-Per-Use Pricing Program Positively Received by Hospitals to Enhance Patient Safety and Reduce Narcotic

TUCSON, AZ, Jul 30 (MARKET WIRE) --
CDEX Inc. (OTCBB: CEXI) (www.cdexinc.com), the developers and marketers
of the ValiMed(TM) Medication Validation System for the in-patient
hospital pharmacy, implemented a new and innovative pricing plan which
allows hospitals to afford this life saving medication safety technology
on a "Pay-Per-Use" basis.

"By also offering a Pay-Per-Use Pricing as an alternative to capital
purchase, CDEX positions its ValiMed technology to be in reach of every
hospital no matter size or specialty," said Greg Firmbach, Senior Vice
President of CDEX. "Pay-Per-Use pricing is an all inclusive turnkey
approach to placing life-saving technology with equipment, supplies and
service all for around $2.50 per test. The reaction in the marketplace has
been very positive as hospitals are now reviewing the integration of
multiple ValiMed units into their medication safety programs for only the
cost of supplies, an operating budget item."

ValiMed is used to validate "The Right Drug at The Right Dose" when
high-risk liquid medications are compounded in a pharmacy setting and also
as a verification program to reduce the diversion of return narcotics in
hospitals and other healthcare facilities. CDEX expects demand to continue
to build as the health system pharmacists, patient safety agencies and
associations and the Joint Commission become more aware of the
availability of ValiMed at these prices.

About CDEX

CDEX develops, manufactures and globally distributes products to the
healthcare and security markets. The ValiMed(TM) product line provides
life-saving validation of high-risk medications and returned narcotics.
The ID2(TM) product line detects trace amounts of illegal drugs, such as
methamphetamine. CDEX expects to advance its patented technologies to
serve additional markets. To meet its plans, CDEX must strengthen its
financial position as stated periodically in its SEC filings. For more
information, contact Malcolm Philips at mphilips@cdex-inc.com.

Non-historical statements are forward-looking, as defined in federal
securities laws, and generally can be identified by words such as
"expects," "plans, " "may," "believes," "should," "intends," and similar
words. These statements pose risks and uncertainties that cannot be
accurately predicted or quantified and, consequently, actual results may
differ materially from those expressed or implied. Such risks and
uncertainties include, without limitation, the effectiveness,
profitability and marketability of products, the protection of
intellectual property and proprietary information, and other risks
detailed periodically in filings with the SEC. There is no obligation to
update any forward-looking statements

Contact:
Malcolm Philips
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-